JP2018511325A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018511325A5 JP2018511325A5 JP2017550936A JP2017550936A JP2018511325A5 JP 2018511325 A5 JP2018511325 A5 JP 2018511325A5 JP 2017550936 A JP2017550936 A JP 2017550936A JP 2017550936 A JP2017550936 A JP 2017550936A JP 2018511325 A5 JP2018511325 A5 JP 2018511325A5
- Authority
- JP
- Japan
- Prior art keywords
- got1
- polypeptide
- purifying
- preparation
- sumo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229920001184 polypeptide Polymers 0.000 claims 9
- 238000002360 preparation method Methods 0.000 claims 6
- 102000037240 fusion proteins Human genes 0.000 claims 4
- 108020001507 fusion proteins Proteins 0.000 claims 4
- 235000018102 proteins Nutrition 0.000 claims 4
- 102000004169 proteins and genes Human genes 0.000 claims 4
- 108090000623 proteins and genes Proteins 0.000 claims 4
- 208000008581 Brain Disease Diseases 0.000 claims 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 210000003169 Central Nervous System Anatomy 0.000 claims 1
- 206010008120 Cerebral ischaemia Diseases 0.000 claims 1
- 229940049906 Glutamate Drugs 0.000 claims 1
- 229960002989 Glutamic Acid Drugs 0.000 claims 1
- 206010053643 Neurodegenerative disease Diseases 0.000 claims 1
- KHPXUQMNIQBQEV-UHFFFAOYSA-N Oxaloacetic acid Chemical compound OC(=O)CC(=O)C(O)=O KHPXUQMNIQBQEV-UHFFFAOYSA-N 0.000 claims 1
- 235000004279 alanine Nutrition 0.000 claims 1
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 claims 1
- 238000005571 anion exchange chromatography Methods 0.000 claims 1
- 201000006474 brain ischemia Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 238000005277 cation exchange chromatography Methods 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 238000004587 chromatography analysis Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 235000013922 glutamic acid Nutrition 0.000 claims 1
- 239000004220 glutamic acid Substances 0.000 claims 1
- 238000010438 heat treatment Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 238000001556 precipitation Methods 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
Claims (5)
- グルタミン酸オキサロ酢酸トランスアミナーゼ1(GOT1)ポリペプチド分子を含むタンパク質調製物であって、前記GOT1ポリペプチド分子の100%が、前記GOT1ポリペプチドの1位にアラニンを有し、前記GOT1ポリペプチドが、配列番号2に示されるアミノ酸配列からなり、前記GOT1ポリペプチド分子は、前記調製物中のタンパク質の100%を構成する、タンパク質調製物。
- 活性な作用物質として請求項1に記載のタンパク質調製物、および薬学的に許容され得る担体を含む、薬学的組成物。
- 過剰なグルタメートに関連する疾患または状態の処置に使用される、請求項1に記載の調製物または請求項2に記載の薬学的組成物。
- 前記疾患または状態が脳の疾患または状態であり、前記脳の疾患が中枢神経系の癌、脳虚血および神経変性疾患からなる群より選択される、請求項3に記載の調整物または薬学的組成物。
- GOT1ポリペプチドを精製する方法であって、前記方法は、
(a)前記GOT1ポリペプチドおよびSUMOを含む融合タンパク質を宿主細胞において発現させる工程であって、前記GOT1ポリペプチドのN末端は、前記SUMOのC末端に翻訳段階で融合され、前記融合タンパク質は、前記SUMOまたは前記GOT1に天然には含まれないいかなるアミノ酸配列も欠く、工程;
(b)前記宿主細胞を破壊し、前記融合タンパク質を放出させる工程、
(c)前記融合タンパク質から前記SUMOを除去する工程;および
(d)前記宿主細胞から前記GOT1ポリペプチドを単離する工程であって、前記単離する工程は、
(i)熱処理によって前記GOT1を精製する工程;
(ii)塩誘導沈殿によって前記GOT1を精製する工程;
(iii)混合モードクロマトグラフィーによって前記GOT1を精製する工程;
(iv)陽イオン交換クロマトグラフィーによって前記GOT1を精製する工程;および
(v)陰イオン交換クロマトグラフィーによって前記GOT1を精製する工程
によって実施され、ここで、工程(c)および(d)は、工程(a)および(b)の後に行われ、工程(v)は、工程(iv)の後に行われ、工程(iv)は、工程(iii)の後に行われ、工程(ii)は、工程(i)の後に行われるものである、工程と、を含む、方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562140492P | 2015-03-31 | 2015-03-31 | |
US62/140,492 | 2015-03-31 | ||
PCT/IL2016/050346 WO2016157190A1 (en) | 2015-03-31 | 2016-03-31 | Glutamate oxaloacetate transaminase 1 (got1), preparations and methods of generating same and uses thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2018511325A JP2018511325A (ja) | 2018-04-26 |
JP2018511325A5 true JP2018511325A5 (ja) | 2019-04-11 |
Family
ID=55795016
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017550936A Pending JP2018511325A (ja) | 2015-03-31 | 2016-03-31 | グルタミン酸オキサロ酢酸トランスアミナーゼ1(got1)、その調製物および製造方法およびその使用 |
Country Status (11)
Country | Link |
---|---|
US (1) | US20180071369A1 (ja) |
EP (1) | EP3277308A1 (ja) |
JP (1) | JP2018511325A (ja) |
KR (1) | KR20170132293A (ja) |
CN (1) | CN107771217A (ja) |
AU (1) | AU2016242298A1 (ja) |
BR (1) | BR112017021016A2 (ja) |
CA (1) | CA2979309A1 (ja) |
HK (1) | HK1243329A1 (ja) |
RU (1) | RU2017135552A (ja) |
WO (1) | WO2016157190A1 (ja) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018229764A1 (en) | 2017-06-13 | 2018-12-20 | Yeda Research And Development Co. Ltd. | Treatment of advanced or progressive multiple sclerosis |
RU2712193C1 (ru) * | 2018-07-27 | 2020-01-24 | Общество с ограниченной ответственностью научно-технический центр "БиоКлиникум" (ООО НТЦ "БиоКлиникум") | Способ лечения поражения нервной системы с помощью рекомбинантной глутаматоксалоацетаттрансаминазы |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL154600B (nl) | 1971-02-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen. |
NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
NL154599B (nl) | 1970-12-28 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking. |
US3901654A (en) | 1971-06-21 | 1975-08-26 | Biological Developments | Receptor assays of biologically active compounds employing biologically specific receptors |
US3853987A (en) | 1971-09-01 | 1974-12-10 | W Dreyer | Immunological reagent and radioimmuno assay |
US3867517A (en) | 1971-12-21 | 1975-02-18 | Abbott Lab | Direct radioimmunoassay for antigens and their antibodies |
NL171930C (nl) | 1972-05-11 | 1983-06-01 | Akzo Nv | Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen. |
US3850578A (en) | 1973-03-12 | 1974-11-26 | H Mcconnell | Process for assaying for biologically active molecules |
US3935074A (en) | 1973-12-17 | 1976-01-27 | Syva Company | Antibody steric hindrance immunoassay with two antibodies |
US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
US4034074A (en) | 1974-09-19 | 1977-07-05 | The Board Of Trustees Of Leland Stanford Junior University | Universal reagent 2-site immunoradiometric assay using labelled anti (IgG) |
US3984533A (en) | 1975-11-13 | 1976-10-05 | General Electric Company | Electrophoretic method of detecting antigen-antibody reaction |
US4098876A (en) | 1976-10-26 | 1978-07-04 | Corning Glass Works | Reverse sandwich immunoassay |
US4879219A (en) | 1980-09-19 | 1989-11-07 | General Hospital Corporation | Immunoassay utilizing monoclonal high affinity IgM antibodies |
US5011771A (en) | 1984-04-12 | 1991-04-30 | The General Hospital Corporation | Multiepitopic immunometric assay |
US4666828A (en) | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US4801531A (en) | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
US5464764A (en) | 1989-08-22 | 1995-11-07 | University Of Utah Research Foundation | Positive-negative selection methods and vectors |
US5192659A (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
US5281521A (en) | 1992-07-20 | 1994-01-25 | The Trustees Of The University Of Pennsylvania | Modified avidin-biotin technique |
AU2003205053B2 (en) * | 2002-01-07 | 2008-10-16 | Lifesensors, Inc. | Methods and compositions for protein expression and purification |
AU2003247143B2 (en) * | 2002-08-01 | 2009-07-16 | Yeda Research And Development Co. Ltd. | Method and composition for protecting neuronal tissue from damage induced by elevated glutamate levels |
GB0315248D0 (en) * | 2003-06-30 | 2003-08-06 | Hoffmann La Roche | HCV regulated protein expression |
WO2006069610A2 (en) * | 2004-07-02 | 2006-07-06 | Metanomics Gmbh | Process for the production of fine chemicals |
EP2096177A3 (en) * | 2004-12-17 | 2010-01-13 | Metanomics GmbH | Process for the production of lutein |
US8119369B2 (en) | 2004-12-30 | 2012-02-21 | Lifesensors, Inc. | Human SUMO-3 for enhancing protein expression |
US20100048480A1 (en) * | 2006-11-22 | 2010-02-25 | Bettina Bommarius | Production of anti-microbial peptides |
EP2109673B1 (en) * | 2006-12-29 | 2015-03-11 | Lifesensors, Inc. | Methods and compositions for enhanced protein expression and purification |
ES2534936T3 (es) * | 2010-08-02 | 2015-04-30 | Ratiopharm Gmbh | Método para producir y purificar una sialiltransferasa soluble activa |
ES2525573T3 (es) * | 2011-05-24 | 2014-12-26 | Asociación Centro De Investigación Cooperativa En Biociencias-Cic Biogune | Trampas de SUMO de alta afinidad |
-
2016
- 2016-03-31 US US15/561,053 patent/US20180071369A1/en not_active Abandoned
- 2016-03-31 JP JP2017550936A patent/JP2018511325A/ja active Pending
- 2016-03-31 AU AU2016242298A patent/AU2016242298A1/en not_active Abandoned
- 2016-03-31 RU RU2017135552A patent/RU2017135552A/ru not_active Application Discontinuation
- 2016-03-31 BR BR112017021016-9A patent/BR112017021016A2/pt not_active Application Discontinuation
- 2016-03-31 WO PCT/IL2016/050346 patent/WO2016157190A1/en active Application Filing
- 2016-03-31 CN CN201680031560.0A patent/CN107771217A/zh active Pending
- 2016-03-31 EP EP16717478.8A patent/EP3277308A1/en not_active Withdrawn
- 2016-03-31 CA CA2979309A patent/CA2979309A1/en not_active Abandoned
- 2016-03-31 KR KR1020177031382A patent/KR20170132293A/ko unknown
-
2018
- 2018-02-27 HK HK18102801.5A patent/HK1243329A1/zh unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20192314T1 (hr) | Pripravci faktora viii i postupci pripreme i njihove uporabe | |
JP2012522736A5 (ja) | ||
US20180214579A1 (en) | Polynucleotide compositions containing amino acids | |
JP2017529097A5 (ja) | ||
HRP20201031T1 (hr) | Anti-ctla-4 protutijela i postupci njihove upotrebe | |
JP2016519137A5 (ja) | ||
JP2018510132A5 (ja) | ||
JP2011528896A5 (ja) | ||
IL278014B2 (en) | Anti-myostatin antibodies, polypeptides containing variable FC regions and methods of use | |
ES2662529T3 (es) | Procedimiento para mejorar la eliminación de virus en la purificación de proteínas | |
RU2018113505A (ru) | Il-8-связывающие антитела и их применения | |
JP2011525523A5 (ja) | ||
JP2010502207A5 (ja) | ||
JP2013537416A5 (ja) | ||
JP2016526885A5 (ja) | ||
JP2013236633A5 (ja) | ||
JP2014523238A5 (ja) | ||
IL288541B (en) | vaccine against rsv | |
BR0211807A (pt) | Derivados ativos amino-ftalazinona como inibidores de cinase, processo para sua preparação e composições farmacêuticas para os mesmos | |
JP2014520142A5 (ja) | ||
JP2016501829A5 (ja) | ||
JP2017529870A5 (ja) | ||
JP2018511325A5 (ja) | ||
RU2015122666A (ru) | Полипептиды для переноса через гематоэнцефалический барьер | |
JP2015509506A5 (ja) |